Loading…
← CockpitCompetitor Analysis › OXB.L Oxford BioMedica plcOpen in the cockpit ↗

Oxford BioMedica plcOXB.LCompetitor analysis, valuation and peers

United Kingdom · GBP·Health Care›Biotechnology
Momentum weak 38
Mkt cap
$841M
US dollars, full cap
Free float
55%
of shares outstanding
$/day
$1.78M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-33.5 pp
WACC 16.5%
Hurdle
n/a
no reverse DCF
Next earnings
148 days
15 Apr 2027
Close · GBP£527.00
1D-1.1%
1W-5.0%
1M+1.1%
3M+3.9%
6M-14.7%
YTD-14.6%
1Y-11.3%
ATR %4.7%
52w lowhigh45.2% off high

What Oxford BioMedica does

Employees: 986

Oxford BioMedica at a glance

Size Oxford BioMedica (OXB.L) is a United Kingdom Health Care company (Biotechnology) with a market value of $841M, the 233rd largest of 355 United Kingdom companies the cockpit tracks. Shares closed at £527.00 on 18 Nov 2026.

Performance Over six months the shares fell 14.7%, against -15.8% for the median peer and +0.1% for the United Kingdom market (cap-weighted) — 9th highest of 19 in its peer set.

Growth Revenue grew 16.0% over the last twelve months (peer median +1.8%); the operating margin is -18.2% (peer median -28.8%).

Valuation It trades at 4.1× enterprise value to sales against a peer median of 6.6× (6th cheapest of 18).

Capital Return on invested capital runs 33.5 points below its cost of capital (16.5% WACC).

Next results Next results expected around 15 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 86OXB.L 84
Six months, rebased to 100: Oxford BioMedica against the median of its 20 peers (local-currency closes).

Oxford BioMedica financials

Reported figures in GBP; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue£175M£169M£129M£89.5M£140M
Revenue growth—+31%+44%-36%—
Gross profit£62.7M£65.3M£52.4M£39.2M£69.1M
EBITDA-£13.3M-£9.12M-£23.3M-£60.1M-£28.3M
Net income-£40.7M-£30.1M-£43.2M-£157M-£39.2M
Free cash flow-£32.5M-£6.46M-£58.1M-£38.2M-£33.0M
Capital expenditure£10.4M£4.76M£7.50M£9.83M£16.3M
Total debtn/a£148M£109M£111M£114M

Quarterly statements and history in the cockpit →

Oxford BioMedica competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%VSTMMGTX45872160688526300841ODTXGLUE688253SNDX6001959887IVAAURA688276SGPOXB.L6-month return →1-month return →
Up and to the right = strong over both horizons. Oxford BioMedica is the large dot.

Fundamentals: revenue growth against valuation

0%+500%+1,000%0×5,000×10,000×VSTMMGTX45872160IVAAPMDOXB.LRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Oxford BioMedica is the large dot.

Oxford BioMedica competitors and peer comparison

How Oxford BioMedica compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Oxford BioMedica against its 20 peers (data as of 18 Nov 2026)
MeasureOXB.LPeer medianRank in peer set
1-month return+1.1%-7.2%6th highest of 21
6-month return-14.7%-15.8%9th highest of 19
Distance from 52-week high-45.2%-42.8%10th lowest of 21
Revenue growth (TTM)+16.0%+1.8%7th highest of 17
Operating margin-18.2%-28.8%7th highest of 18
EV / Sales4.1×6.6×6th cheapest of 18
ROIC minus cost of capital-33.5 pp-7.0 pp3rd lowest of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Oxford BioMedica OXB.LUnited Kingdom$841M-15%+16%-18%4.1×n/an/a
Verastem VSTMUnited States$866M+66%+650%-194%8.2×n/an/a
MeiraGTx MGTXUnited States$813M-13%+1,366%44%1.9×n/an/a
Peptidream 4587.TJapan$878M-3%+14%-18%6.6×n/an/a
GNI 2160.TJapan$903M-25%+44%-21%6.2×n/an/a
Wuhan Keqian Biology 688526.SSChina$780M-24%-22%20%4.4×7.8%+2.4%
Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZChina$909M-15%0%22%4.2×9.2%+2.3%
Odyssey Therapeutics ODTXUnited States$912M+12%-33%-5,415%204.9×n/an/a
Monte Rosa Therapeutics GLUEUnited States$775M-51%-61%-214%3.3×n/an/a
Innovita Biological Technology 688253.SSChina$915M-28%-28%11%14.0×39.6%-16.6%
Syndax Pharmaceuticals SNDXUnited States$771M-57%+160%-62%3.2×n/an/a
China Animal Husbandry Industry 600195.SSChina$921M-16%+1%2%1.3×6.1%+4.4%
Nanjing Leads Biolabs 9887.HKHong Kong$764M-50%n/a-108%21.1×n/an/a
Inventiva IVA.PAFrance$763M-36%-100%-307,063%12,169.8×n/an/a
Aura Biosciences AURAUnited States$743M-4%n/an/an/an/an/a
Beijing SL Pharmaceutical 002038.SZChina$736M-20%-4%-119%6.9×-13.5%-10.9%
Apnimed APMDUnited States$726Mn/a+380%-140%10.8×n/an/a
R&G PharmaStudies 301333.SZChina$722M-11%+21%11%3.4×17.3%+11.8%
Shaanxi Micot Pharmaceutical Technology 2335.HKHong Kong$715Mn/an/an/an/an/an/a
Changchun BCHT Biotechnology 688276.SSChina$992M-2%+2%-29%9.9×n/an/a
SpyGlass Pharma SGPUnited States$993M+36%n/an/an/an/an/a

Questions

Which companies are Oxford BioMedica's closest peers?
The cockpit's peer set: Verastem (VSTM), MeiraGTx (MGTX), Peptidream (4587.T), GNI (2160.T), Wuhan Keqian Biology (688526.SS), Chengdu Kanghua Biological Products Co. Td Class 1 (300841.SZ), Odyssey Therapeutics (ODTX), Monte Rosa Therapeutics (GLUE).
Is Oxford BioMedica expensive compared with its peers?
On ev / sales it trades at 4.1× against a peer median of 6.6×, 6th cheapest of 18 in its peer set.
How has Oxford BioMedica stock performed?
Over six months to 18 Nov 2026 the shares returned -14.7% against -15.8% for the median peer; over one year -11.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.